INDUSTRY INSIGHTS
Efficacy of xanomeline and trospium chloride in schizophrenia: pooled results from three 5-week, randomized, double-blind, placebo-controlled, EMERGENT trials
A pooled analysis of three clinical trials tested a new treatment...
September 30, 2025
INDUSTRY INSIGHTS
Mental Health and TD Diverse Communities Factsheet
This document by Neurocrine Biosciences, INC discusses how serious...
September 25, 2025
INDUSTRY INSIGHTS
Test Your TD Knowledge Fact Sheet
This handout provided by Neurocrine Biosciences, INC breaks down...
September 19, 2025
INDUSTRY INSIGHTS
Safety and tolerability of xanomeline and trospium chloride in schizophrenia: pooled results from three 5-week, randomized, double-blind, placebo-controlled, EMERGENT trials
This study looked at a new treatment for schizophrenia that combines...
September 10, 2025
INDUSTRY INSIGHTS
Muscarinic Acetylcholine Receptor Agonists as Novel Treatments for Schizophrenia
Muscarinic receptor agonists are an emerging area of research in...
September 8, 2025
INDUSTRY INSIGHTS
MIND TD - When Talking To Patients, Remember "MIND - TD"
This document developed by Neurocrine Biosciences, Inc is an educational...
September 7, 2025
INDUSTRY INSIGHTS
PRIDE Study (Paliperidone Palmitate Research in Demonstrating Effectiveness)
The PRIDE study conducted by Janssen Pharmaceuticals, compared...
September 1, 2025
